FIELD: medicine.
SUBSTANCE: invention refers to medicine, and concerns mediated PHKi inhibition of RHO-kinase for treating ophthalmic disorders. The substance of the invention involves RNA-interference for mRNA Rho-kinase expression inhibition for treating patients with ophthalmic disorders, especially for treating intraocular pressure, eye hypertension and glaucoma The mRNA Rho-kinase targets include gene ROCK 1 mRNA.
EFFECT: creation of the agent exhibiting improved properties.
56 cl, 2 ex, 4 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| iRNA-MEDIATED INHIBITION OF TUMOUR NECROSIS FACTOR-( RELATED CONDITIONS | 2007 |
|
RU2469090C2 |
| TREATMENT OF CNS DISORDERS | 2007 |
|
RU2426544C2 |
| TREATMENT OF DISEASES ASSOCIATED WITH ERYTHROPOIETIN (EPO) BY NATURAL EPO ANTISENSE TRANSCRIPT INHIBITION | 2009 |
|
RU2620970C2 |
| HSP47 EXPRESSION MODULATION | 2010 |
|
RU2575056C2 |
| TREATING SIRTIUN 1 (SIRT1)-RELATED DISEASES BY INHIBITON OF NATURAL ANTISENSE TRANSCRIPT | 2009 |
|
RU2551234C2 |
| METHODS FOR TREATMENT OF HEPATITIS B INFECTION | 2018 |
|
RU2780021C2 |
| siPHK-BASED TREATMENT OF EYE DISEASE CHARACTERISED BY HIGH INTRAOCULAR PRESSURE | 2005 |
|
RU2407531C2 |
| TREATMENT OF INTERFERON-RELATED DEVELOPMENTAL REGULATOR 1 (IFRD1) ASSOCIATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IFRD1 | 2011 |
|
RU2611195C2 |
| RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | 2011 |
|
RU2624045C2 |
| TREATMENT OF DISEASES RELATED WITH GENE DLG BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT OF DLG GENE | 2011 |
|
RU2611190C2 |
